top of page
The Sound of Evolution
Sunitinib
Mechanism of action:
Sunitinib is a multi-target receptor tyrosine kinase inhibitor. It inhibits multiple receptor tyrosine kinases, including VEGFR-1, VEGFR-2, and VEGFR-3 (vascular endothelial growth factor receptors), as well as PDGFR-a and PDGFR-b (platelet-derived growth factor receptors), thereby suppressing tumor angiogenesis.
Reference(s):
1. Motzer RJ et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med.
2. Demetri GD et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet.
bottom of page